Monkeypox vaccines (ACAM2000, JYNNEOS, modified vaccinia Ankara) pose cardiovascular risks, especially in young men. ACAM2000 is linked to severe events like myocarditis, while JYNNEOS and modified vaccinia have minor effects. A literature review suggests vaccine-related heart damage may be due to antibody attacks. Given Monkeypox's mild nature treated with tecovirimat, wide vaccination risks increased heart failure and sudden deaths, particularly in the Congo. Further research on vaccine safety is essential.
Concerns Over Cardiac Side Effects from Monkeypox Vaccination Review Cites Heart Toxicity with All Three Products Sat, 07 Sep 2024 09:16:49 GMT https://petermcculloughmd.substack.com/p/concerns-over-cardiac-side-effects By Peter A. McCullough, MD, MPH
Monkeypox vaccines include ACAM2000 (used for Smallpox, recently FDA approved for Monkeypox), JYNNEOS, and modified vaccinia Ankara. The at-risk population is young men who are at the highest risk of idiopathic and COVID-19 vaccine myocarditis at baseline. ACAM2000 has been reported to have major cardiovascular adverse events such as myocarditis, dilated cardiomyopathy, and heart failure. Whereas JYNNEOS and modified vaccinia Ankara are associated with minor cardiovascular adverse events such as tachycardia, palpitation, electrocardiogram changes such as T wave inversion, and ST elevation in the peer-reviewed literature. The CDC has reported serious myocarditis from the Bavarian Nordic JYNNEOS vaccine requiring hospitalization of young men.
Shrestha AB, Mehta A, Zahid MJ, Candelario K, Shrestha S, Pokharel P. Concerns over cardiovascular manifestations associated with monkeypox immunization: a literature review. Ann Med Surg (Lond). 2023 May 19;85(6):2797-2801. doi: 10.1097/MS9.0000000000000861. PMID: 37363545; PMCID: PMC10289523.
A review by Shreshtha et al indicates heart damage from Monkeypox vaccination may come from an off-target attack on the heart by antibodies raised by the vaccines. The paper concludes more research is needed for safer vaccines.
Because Monkeypox is largely a self-limited skin rash in immunocompetent individuals and easily treated with oral or intravenous tecovirimat, vaccination is a high-risk public health intervention and if widely applied in the Congo we can expect to see rising numbers heart failure and sudden death in vaccine recipients.
Courageous Discourse™ with Dr. Peter McCullough & John Leake is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
Please subscribe to Courageous Discourse as a paying ($5 monthly) or founder member so we can continue to bring you the truth.
Peter A. McCullough, MD, MPH
President, McCullough Foundation
Shrestha AB, Mehta A, Zahid MJ, Candelario K, Shrestha S, Pokharel P. Concerns over cardiovascular manifestations associated with monkeypox immunization: a literature review. Ann Med Surg (Lond). 2023 May 19;85(6):2797-2801. doi: 10.1097/MS9.0000000000000861. PMID: 37363545; PMCID: PMC10289523.
Duffy J, Marquez P, Moro P, et al. Safety Monitoring of JYNNEOS Vaccine During the 2022 Mpox Outbreak — United States, May 22–October 21, 2022. MMWR Morb Mortal Wkly Rep 2022;71:1555–1559. DOI: http://dx.doi.org/10.15585/mmwr.mm7149a4